

April 5, 2011

ORIGIO a/s  
A world leader in Assisted Reproductive Technologies (ART)

### **Purchase of shares by utilization of warrants**

Charlotte Witttrup (former ORIGIO employee) has utilized her warrants and bought 50,000 shares at a rate of DKK 11.45 per share at nominally DKK 5. The exercise price of the warrants equals the market price of the ORIGIO shares as at November 11, 2005.

The total nominal value of ORIGIO a/s' share capital registered with the Danish Commerce and Companies Agency (Erhvervs- & Selskabsstyrelsen) is hereafter DKK 145,828,475. The share capital comprises 29,165,695 shares of a nominal value of DKK 5, each corresponding to 29,165,695 votes.

*For further information, please contact:*

*Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or email, [jbrix@origio.com](mailto:jbrix@origio.com)*

#### **About ORIGIO a/s**

*ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the three product families, MediCult Media, Humagen Pipets and MidAtlantic Devices, that cater for the broadest range of ART requirements. The Medtech company ORIGIO, which is headquartered in Måløv, Denmark, and has subsidiaries in 10 countries, is listed on the Oslo Stock Exchange under the symbol, ORO. For further information, please visit [www.origio.com](http://www.origio.com).*

#### **Forward-Looking Statements**

*Certain statements in this announcement contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this announcement will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO's anticipated schedule. These factors, and other factors including, but not limited to, those described in ORIGIO's most recent annual report, could cause future results to differ materially from the expectations expressed in this announcement. The forward-looking statements contained in this announcement may become outdated over time. ORIGIO does not assume any responsibility for updating any forward-looking statements.*